The full list includes: BPC-157 (Body Protection Compound-157) TB-500 (Thymosin Beta-4) MOTS-C (Mitochondrial-derived Peptide) GHK-Cu (Copper-binding Tripeptide) Semax (Synthetic ACTH analog) Selank (Synthetic tuftsin analog) DSIP (Delta Sleep-Inducing Peptide) Epithalon (Epithelial Peptide) Kotan (Derivative of Selank) CG-250 (Radiolabeled somatostatin analog, limited clinical use) N-Acetyl Semax (Semax variant) Dihexa (Angiotensin IV analog, nootropic applications) The announcement did not move these peptides to Category 1 a distinction that matters
If tirzepatide is clinically superior in weight loss percentage, why wouldn't every patient start there
One randomized controlled trial (RCT) found that exenatide (2 mg weekly for 6 weeks), when combined with a nicotine replacement therapy patch, reduced nicotine cravings, withdrawal symptoms, and post-cessation weight gain, and increased nicotine abstinence compared to placebo or nicotine replacement therapy alone, in individuals who had smoked for at least a year and consumed 10 cigarettes daily [21]
A 2020 study in Diabetes Care found that evening insulin sensitivity was 45% lower than morning sensitivity in healthy adults, and this gap widened to 60% in individuals with impaired glucose tolerance
Peptides, such as the ones mentioned earlier, help in reducing exercise-induced damage, thereby speeding up recovery